- Home
- SOPA vs APVO Comparison
SOPA vs APVO Comparison
Compare SOPA & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOPA
- APVO
- Stock Information
- Founded
- SOPA 2018
- APVO 2016
- Country
- SOPA Singapore
- APVO United States
- Employees
- SOPA N/A
- APVO N/A
- Industry
- SOPA EDP Services
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- SOPA Technology
- APVO Health Care
- Exchange
- SOPA Nasdaq
- APVO Nasdaq
- Market Cap
- SOPA 3.8M
- APVO 4.1M
- IPO Year
- SOPA 2021
- APVO N/A
- Fundamental
- Price
- SOPA $1.25
- APVO $3.06
- Analyst Decision
- SOPA Strong Buy
- APVO Strong Buy
- Analyst Count
- SOPA 1
- APVO 1
- Target Price
- SOPA $15.00
- APVO $5,920.00
- AVG Volume (30 Days)
- SOPA 106.3K
- APVO 191.0K
- Earning Date
- SOPA 08-18-2025
- APVO 08-07-2025
- Dividend Yield
- SOPA N/A
- APVO N/A
- EPS Growth
- SOPA N/A
- APVO N/A
- EPS
- SOPA N/A
- APVO N/A
- Revenue
- SOPA $6,731,955.00
- APVO N/A
- Revenue This Year
- SOPA N/A
- APVO N/A
- Revenue Next Year
- SOPA $45.16
- APVO N/A
- P/E Ratio
- SOPA N/A
- APVO N/A
- Revenue Growth
- SOPA N/A
- APVO N/A
- 52 Week Low
- SOPA $0.64
- APVO $2.81
- 52 Week High
- SOPA $6.75
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- SOPA 47.70
- APVO 38.28
- Support Level
- SOPA $1.23
- APVO $3.01
- Resistance Level
- SOPA $1.35
- APVO $3.18
- Average True Range (ATR)
- SOPA 0.06
- APVO 0.16
- MACD
- SOPA -0.00
- APVO 0.19
- Stochastic Oscillator
- SOPA 45.45
- APVO 45.45
About SOPA Society Pass Incorporated
Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with entrepreneurs, the company meets the growing demand for services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Corporate. The company generates the majority of its revenue from the Digital marketing segment.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.